<![CDATA[Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer]]>
The combination of sacituzumab govitecan-hziy (Trodelvy) and trastuzumab (Herceptin) elicited an overall response rate (ORR) of 3.7% (95% CI, 0.1%-19%) in patients with HER2-positive metastatic breast cancer who had previously received fam-trastuzumab …